OliX PharmaceuticalsInc
OliX Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing RNA interference (RNAi) therapeutics for dermal, ophthalmic, and pulmonary diseases. The company's products pipeline includes OLX101A for skin scar; OLX104C for androgenic alopecia; OLX301A for age-related macular degeneration; OLX702A for metabolic dysfunction-associated steatohepatitis; OLX703A for hepati… Read more
OliX PharmaceuticalsInc (226950) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.023x
Based on the latest financial reports, OliX PharmaceuticalsInc (226950) has a cash flow conversion efficiency ratio of 0.023x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩3.23 Billion) by net assets (₩142.56 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
OliX PharmaceuticalsInc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how OliX PharmaceuticalsInc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
OliX PharmaceuticalsInc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of OliX PharmaceuticalsInc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Oberbank AG
VI:OBS
|
-0.099x |
|
Deciphera Pharmaceuticals Inc
F:D05
|
-0.173x |
|
MORGAN SINDALL GRP LS-05
F:0KN
|
N/A |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
0.042x |
|
Andon Health Co Ltd
SHE:002432
|
0.023x |
|
Indra Sistemas S.A
OTCGREY:ISMAF
|
0.005x |
|
Hisamitsu Pharmaceutical Co. Inc
F:HPX
|
N/A |
|
Chongqing Zongshen Power Machinery Co Ltd
SHE:001696
|
0.021x |
Annual Cash Flow Conversion Efficiency for OliX PharmaceuticalsInc (2016–2024)
The table below shows the annual cash flow conversion efficiency of OliX PharmaceuticalsInc from 2016 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩17.85 Billion | ₩-28.04 Billion | -1.571x | -273.62% |
| 2023-12-31 | ₩50.34 Billion | ₩-21.17 Billion | -0.421x | +9.67% |
| 2022-12-31 | ₩65.91 Billion | ₩-30.68 Billion | -0.466x | +54.75% |
| 2021-12-31 | ₩18.52 Billion | ₩-19.05 Billion | -1.029x | -1139.29% |
| 2020-12-31 | ₩45.29 Billion | ₩-3.76 Billion | -0.083x | +67.67% |
| 2019-12-31 | ₩41.80 Billion | ₩-10.73 Billion | -0.257x | -68.76% |
| 2018-12-31 | ₩54.94 Billion | ₩-8.36 Billion | -0.152x | +40.64% |
| 2017-12-31 | ₩18.68 Billion | ₩-4.79 Billion | -0.256x | +6.67% |
| 2016-12-31 | ₩12.56 Billion | ₩-3.45 Billion | -0.275x | -- |